Integra LifeSciences Holdings Corporation (NASDAQ:IART) shares traded lower over the last trading session, losing -0.78% on 05/20/21. The shares fell to a low of $69.71 before closing at $70.95. Intraday shares traded counted 0.52 million, which was -41.65% lower than its 30-day average trading volume of 369.50K. IART’s previous close was $71.51 while the outstanding shares total 84.50M. The firm has a beta of 1.23, a 12-month trailing P/E ratio of 35.46, and a growth ratio of 2.04. The stock’s Relative Strength Index (RSI) is 44.85, with weekly volatility at 2.21% and ATR at 1.96. The IART stock’s 52-week price range has touched low of $42.12 and a $77.40 high.
Investors have identified the Medical Devices company Integra LifeSciences Holdings Corporation as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $5.99 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Integra LifeSciences Holdings Corporation (IART) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For IART, the company has in raw cash 408.98 million on their books with 110.9 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 1.04 billion total, with 412.3 million as their total liabilities.
IART were able to record 62.41 million as free cash flow during the 07/28/2021 quarter of the year, this saw their quarterly net cash flow reduce by -61.19 million. In cash movements, the company had a total of 69.08 million as operating cash flow.
Potential earnings growth for Integra LifeSciences Holdings Corporation (IART)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 07/28/2021 quarter of the year, Integra LifeSciences Holdings Corporation recorded a total of 360.07 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 1.6% coming in sequential stages and their sales for the 07/28/2021 quarter reducing by -7.94%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 145.82 million trying to sell their products during the last quarter, with the result yielding a gross income of 214.25 million. This allows shareholders to hold on to 84.50M with the recently reported earning now reading 0.54 cents per share. This is a figure that compared to analyst’s prediction for their 07/28/2021 (0.69 cents a share).
Having a look at the company’s valuation, the company is expected to record 3.36 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on IART sounds very interesting.
Is the stock of IART attractive?
In related news, Executive Vice President &CHRO, Evoli Lisa sold 5,335 shares of the company’s stock in a transaction that recorded on May 10. The sale was performed at an average price of 75.00, for a total value of 400,125. As the sale deal closes, the Executive Vice President & COO, Coleman Glenn now sold 25,658 shares of the company’s stock, valued at 1,834,547. Also, Executive Vice President & COO, Coleman Glenn sold 4,002 shares of the company’s stock in a deal that was recorded on Apr 14. The shares were price at an average price of 70.50 per share, with a total market value of 282,141. Following this completion of acquisition, the Executive Vice President &CHRO, Evoli Lisa now holds 6,306 shares of the company’s stock, valued at 441,420. In the last 6 months, insiders have changed their ownership in shares of company stock by 12.30%.
7 out of 14 analysts covering the stock have rated it a Buy, while 5 have maintained a Hold recommendation on Integra LifeSciences Holdings Corporation. 1 analysts has assigned a Sell rating on the IART stock. The 12-month mean consensus price target for the company’s shares has been set at $77.45.